- Home
- Clinical Care
- How early is too early for a new aortic valve? PROGRESS tests the boundary
How early is too early for a new aortic valve? PROGRESS tests the boundary
A new trial finds fewer combined death or heart-failure events in selected patients with moderate stenosis
For someone with a narrowed aortic valve, timing can be as consequential as the choice of procedure. Treat too late and the heart may deteriorate; intervene earlier and a person takes on procedural risks before the disease reaches its traditional treatment threshold. New PROGRESS trial results bring that timing question into sharper focus.
Published in the New England Journal of Medicine on 2 November 2026, the trial tested transcatheter aortic-valve replacement, or TAVR, against clinical surveillance in selected people with moderate aortic stenosis. Its findings invite a more precise discussion about earlier intervention, while leaving important limits around who might benefit.
Moderate describes the valve, not the whole person
The aortic valve controls blood leaving the heart towards the body. Stenosis means its opening has narrowed. The National Heart, Lung, and Blood Institute explains that valve disease can progress over time and may produce fatigue, breathing difficulty, faintness or chest symptoms. An imaging label alone cannot describe a person’s entire clinical situation.
PROGRESS recruited patients who had moderate narrowing together with at least one feature associated with risk, such as a symptom or a relevant structural or functional abnormality. This matters because the study did not ask whether every person with an incidental moderate valve finding should receive an implant.
Its comparison was also an active management decision. Surveillance means following the condition and responding to changes. A useful interpretation therefore compares two strategies over time, rather than describing the control group as receiving no care.
What changed over two years
The international, open-label randomised trial assigned 744 participants to TAVR or surveillance. Their average age was 78. At two years, the estimated proportion experiencing death or a heart-failure event was 16.7% with TAVR and 23.9% with surveillance, an absolute difference of 7.2 percentage points.
The components deserve separate attention. Estimated mortality was 8.4% and 7.3%, respectively, while heart-failure events occurred in 10.8% and 19.0%. The combined result favoured intervention, but the mortality figures do not demonstrate that earlier TAVR helped participants live longer. Edwards Lifesciences funded the study.
That distinction changes the conversation. Avoiding a heart-failure event can matter greatly to a patient, but it is a different claim from extending life. Presenting the combined outcome without its components would make the evidence harder to understand. Patients and clinicians also need to decide how much that possible benefit matters alongside the immediate burden of intervention.
Earlier treatment still involves a procedure
TAVR uses a catheter passed through a blood vessel to place a replacement valve. NHLBI describes it as one route to valve replacement, alongside surgical approaches. Selection depends on the individual’s circumstances, and a less invasive route still carries risks.
Those risks can include stroke, bleeding or damage at the catheter entry site, injury to the kidneys or heart, and leakage around a replacement valve. Continuing care and follow-up remain necessary after implantation. Moving a procedure earlier changes when those burdens are accepted; it does not make them disappear.
A patient considering the findings should therefore ask what outcome the team hopes to prevent and how closely their own situation resembles the trial population. Age, symptoms, anatomy, other illnesses and the source of any breathlessness all belong in an assessment by an experienced valve team.
From a trial result to a treatment pathway
Graymedy’s reading is that PROGRESS challenges a simple wait-for-severe-disease narrative in a defined group. It does not replace specialist judgement with a single new rule. The next practical task is deciding how this evidence fits alongside other studies, guidelines, device indications and local access arrangements.
A Yale Medicine listing for the PROGRESS continued-access study, updated in October 2026, describes moderate calcific stenosis within a research pathway. That listing supplies context about the programme; it does not establish that the November results have already changed routine eligibility everywhere.
Two years of follow-up also answers a different question from the lifetime management of a valve. Longer observation will help clarify how early gains compare with later events and subsequent treatment. Readers should watch for those outcomes as well as the initial headline.
The immediate value is a better informed timing discussion. For selected patients, preventing deterioration may begin before the valve becomes severely narrowed. Establishing who should act earlier requires connecting the trial’s measured benefit with the person’s risks, preferences and longer-term care.
Sources: Généreux and colleagues: PROGRESS, NEJM, 2026; NHLBI: valve disease; NHLBI: valve treatment and risks; Yale: continued-access programme.
Illustration: BruceBlaus / Wikimedia Commons, CC BY 3.0; resized.
Reviewed 4 November 2026. Independently written from public sources; no interview was conducted. General information, not individual medical advice.
Clinical Care
View more
A new US indication for Jemperli (dostarlimab-gxly) brings an organ-preserving approach into the rectal-cancer conversation. The FDA granted accelerated approval on October 19 for previously untreated stage II or III disease with dMMR or MSI-H tumors, confirmed by an authorized test. This is a small, biologically defined group: the agency estimates roughly 3% of locally advanced rectal cancers have these features. The approval does not extend to every rectal cancer. A different pathway, with follow-up still essential In the 154-patient AZUR-1 study, almost three-quarters had avoided surgery, radiotherapy and chemotherapy after a median follow-up exceeding two years. Longer observation is needed to establish how durable the benefit is and how often cancer returns. Dostarlimab can also trigger severe or fatal immune reactions against healthy tissues. Avoiding conventional treatment does not remove the need for specialist care. The practical shift is a more individual discussion of tumor testing, treatment goals and surveillance. Accelerated approval makes an option available while the sponsor continues collecting evidence of lasting clinical benefit. FDA approval and evidence
After the smoke clears, wildfire survivors may still need lung-health follow-up
Women express interest in trials—but few report receiving an invitation
Diet during antibiotics: a transplant study puts the hospital menu under scrutiny
A mobile clinic can remove the journey to a hospital. Whether it can also make treatment easier to sustain is a different question. A new trial led by Steven Shoptaw and Nabila El-Bassel puts both questions into view, with findings that deserve attention without a victory-lap headline. Published on 4 November in JAMA Psychiatry, HPTN 094 compared two ways of connecting people who inject drugs with HIV prevention and opioid-use-disorder services. The mobile-clinic group experienced fewer deaths over a year. Yet the intervention did not significantly improve the trial's main measures of medication use. Both findings matter. The comparison was more demanding than no care The study enrolled 409 adults without HIV in Houston, Los Angeles, New York City, Philadelphia and Washington, D.C. Participants had opioid use disorder, were not receiving medication for it when enrolled, and were willing to consider treatment. They were randomly assigned to one of two approaches. For 26 weeks, the intervention group received peer navigation plus integrated services through a mobile medical unit. These included oral HIV pre-exposure prophylaxis, known as PrEP, addiction medication and limited clinical and supportive services. The comparison group also received peer navigation, connecting people with existing community services. That active comparison is important. The trial tested the extra contribution of bringing services together on a vehicle when navigation was already available. It cannot be read as mobile clinics versus abandonment, or as a test of whether peer support has value. A striking result with a small event count Four deaths were confirmed among 203 people assigned to the mobile intervention, compared with 13 among 206 assigned to community-service navigation. The reported hazard ratio was 0.29, the basis for the widely publicised 71% relative reduction. Mortality was a secondary outcome, and the researchers say the finding needs replication. The absolute numbers make the result easier to judge. Seventeen deaths across the trial are a serious human loss, but a limited foundation for estimating exactly how large a benefit another programme would deliver. The result supports further investigation; it does not establish a guaranteed effect for every city or patient group. Why the main outcomes still matter At 26 weeks, verified PrEP use was 5.4% in the intervention group and 2.9% in the comparison group. Confirmed addiction-medication use was 14.8% and 10.7%, respectively. Neither difference was statistically significant. The findings therefore leave the original challenge of sustained medication engagement unresolved. It would be misleading to turn the survival result into evidence that the programme succeeded on all its objectives. Equally, a headline declaring the service ineffective would overlook a potentially important signal. Different outcomes answer different questions, and a careful assessment keeps them visible together. Shoptaw and El-Bassel are testing a service model The programme brings a practical research question into the street: what changes when care is available near people facing fragmented services, unstable housing or stigma? Shoptaw at UCLA and El-Bassel at Columbia co-chaired the trial. NIH's account describes accessibility as a central reason for studying this approach. The published protocol also describes planning around local HIV and overdose patterns and available services. A clinic's location is part of its intervention. For readers assessing a similar service, the useful questions concern where it stops, when it operates and whether people can return consistently. What should follow the headline Graymedy's interpretation is that the next step should examine both replication and delivery. A larger or independent evaluation could test the mortality signal. Detailed work on treatment entry, interruptions and return could help explain why medication use remained difficult to sustain. Local teams would also need to assess staffing, referral relationships and continuity after the mobile programme ends. Those are implementation questions raised by the findings, not benefits demonstrated by this trial. A vehicle can provide a place for care; the evidence still has to show which parts of the service change outcomes. For people seeking support, this research is a reason to ask about accessible HIV prevention and addiction services locally. It is not a reason to wait for a particular mobile programme. The study's most useful contribution is a sharper question: how can care reach people repeatedly enough to make a lasting difference? For commissioners, the distinction also affects what to measure next. Counting visits alone would miss whether people remain connected to care. A useful evaluation should specify its clinical outcomes in advance and report practical difficulties alongside improvements, so other communities can judge what is transferable. Sources: HPTN 094 trial, JAMA Psychiatry; HPTN results announcement; NIH, 4 November 2026; Published study protocol. Photo: NIH / study clinic; artwork: Shepard Fairey. Reviewed 5 November 2026. Independently written from public sources; no interview was conducted. General information, not individual medical advice.
How early is too early for a new aortic valve? PROGRESS tests the boundary
Starting CPAP: why a follow-up plan matters as much as the machine
Five-year PHERGain results sharpen the question of who may avoid chemotherapy
Leaving the ward is not the end of treatment Hospital discharge can feel like a milestone, but recovery often continues in a less predictable environment. At home, patients and families become responsible for medicines, appointments, wound checks, mobility and recognizing new symptoms. Instructions delivered during a busy final ward round may be difficult to remember, especially after illness, surgery or a long admission. A safer discharge process begins before the patient reaches the exit and follows through once ordinary life resumes. Why the transition is vulnerable Different clinicians may have changed treatment while a patient was hospitalized. A long-standing tablet might have been stopped, a dose adjusted or a temporary prescription added. The final medication list must reconcile these changes with what is already at home. Problems arise when lists conflict, pharmacy supplies are delayed or patients cannot distinguish a new medicine from an old one. Care teams should confirm not merely what has been prescribed but what the patient will actually take. Making instructions understandable A clear plan explains the reason for admission, what improved, what still needs attention and what recovery should look like. Rather than asking whether someone understands, clinicians can invite them to describe the plan in their own words. This teach-back approach exposes misunderstandings without treating questions as a failure. Written guidance in an appropriate language, accessible formatting and a named contact help patients revisit instructions after fatigue or stress has eased. The importance of the first follow-up For some patients, an early telephone or in-person check can uncover difficulties before they become urgent. A nurse, pharmacist or primary-care clinician may ask whether medicines were obtained, symptoms changed, transport is available and a specialist appointment has been booked. The ideal timing depends on the diagnosis and clinical risk; there is no universal seventy-two-hour rule for everyone. Nevertheless, the opening days at home are a practical opportunity to identify unmet needs. Warning signs must be specific Advice to seek help if symptoms worsen is often too vague. Patients benefit from examples that fit their condition and a clear distinction between routine questions and emergencies. After surgery, this may include concerning bleeding, increasing redness or fever; after a breathing-related admission, it may include worsening breathlessness. Severe chest pain, marked difficulty breathing, new confusion or symptoms suggestive of stroke require emergency assessment. Discharge paperwork cannot replace individualized clinical advice. Recovery includes more than medical tests Someone can be medically ready for discharge yet struggle with stairs, food, transportation or caregiving responsibilities. Financial pressure, limited digital access and low health literacy can make a technically correct care plan difficult to follow. Social workers, occupational therapists, community teams and family caregivers may all be relevant. Good discharge planning therefore assesses the patient's living circumstances and what support is realistically available, not just whether vital signs have stabilized. Connecting hospital and community teams A discharge summary should reach the next clinician promptly and explain key findings, medication changes, pending results and requested follow-up. Pending tests are particularly important: somebody must be responsible for reviewing them and informing the patient when action is needed. When hospital and community records do not communicate well, patients may have to repeat their history or resolve contradictory advice. Shared responsibility and explicit handovers reduce that burden. A practical definition of success The goal is not simply to shorten hospital stays or reduce readmission numbers. It is to make the move home safe, comprehensible and sustainable. Providers can learn from patient calls, medication discrepancies, missed appointments and reports of confusion. Patients should leave knowing what to do today, what to expect next and whom to contact if the plan fails. The best discharge is not a stack of instructions; it is a reliable continuation of care. What families can ask before leaving Before discharge, patients and caregivers can ask for one updated medication list, written warning signs and the contact number for problems arising outside office hours. They can clarify who is booking the next appointment and who will communicate any outstanding results. If equipment, dressing supplies or help moving around is required, arrangements should be confirmed rather than assumed. Families should also know which symptoms call for emergency services instead of a routine callback. These questions are not a substitute for professional judgment; they help translate a hospital plan into a realistic set of actions at home.
Pressure-injury prevention starts with a daily plan for the person
Sudden confusion needs urgent care, even when the patient is quiet
